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of LINC00526 is correlated with aggravation and poor survival in glioma. Functional assays revealed that ectopic expression of LINC00526 inhibits glioma cell proliferation, migration, and invasion. LINC00526 silencing promotes glioma cell proliferation, migration and invasion. Mechanistically, we found that LINC00526 directly interacts with EZH2, represses the binding of EZH2 to AXL promoter, attenuates the transcriptional activating roles of EZH2 on AXL, and therefore represses AXL expression. Via repressing AXL, LINC00526 further represses PI3K/Akt/NF-κB signalling. Intriguingly, we identified that NFKB1 and NFKB2 directly binds LINC00526 promoter and represses LINC00526 transcription. We further found that via activating NF-κB signalling, AXL represses LINC00526 transcription. Therefore, LINC00526/EZH2/AXL/ PI3K/Akt/NF-κB form a feedback loop in glioma. Analysis of the TCGA data revealed that the expression of LINC00526 is inversely correlated with that of AXL in glioma tissues. In addition, functional rescue assays revealed that the tumour suppressive roles of LINC00526 are dependent on the negative regulation of AXL. Collectively, our data identified LINC00526 as a tumour suppressor in glioma via forming a double negative feedback loop with AXL. Our data also suggested LINC00526 as a potential prognostic biomarker and therapeutic candidate for glioma.
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| INTRODUC TI ON
Glioma is the most prevalent type of intracranial neoplasm with high morbidity and mortality. 1 Although multiple therapeutic strategies have emerged, including surgical resection, radiotherapy, chemotherapy and so on, the outcomes of glioma patients are still very poor due to the excessive aggressive growth of glioma and resistance to conventional therapies. 2, 3 Therefore, revealing the in-depth molecular pathogenesis of glioma is of great importance to develop efficient therapies for glioma.
Accumulating genome and transcriptome high-throughput sequencings have confirmed that most of human genome is transcribed for non-coding RNAs. 4, 5 For example, Iyer et al identified 58,648 genes transcribing for long non-coding RNAs, and only 21,313 genes encoding for proteins in human cells. 6 Long non-coding RNA (lncRNA) is a class of transcripts with limited protein-coding potential and more than 200 nucleotides in length. 7 Increasing evidences have demonstrated that many lncRNAs are frequently dysregulated in numerous diseases, including cancers. [8] [9] [10] Among these dysregulated lncRNAs, several lncRNAs are further verified to be potential diagnostic and prognostic biomarkers for a variety of cancers. [11] [12] [13] Furthermore, many lncRNAs have important roles in various physiological and pathological processes. [14] [15] [16] As to cancers, numerous lncRNAs have been shown to influence cell proliferation, cell cycle, cell apoptosis, cell senescence, cell migration and invasion, drug-resistance, in vivo tumour growth and metastasis and so on. [17] [18] [19] [20] Therefore, several lncRNAs were identified to be potential therapeutic targets for various cancers. 21 LncRNAs have various and complex regulatory roles in control gene expression, particular for the expressions of critical oncogenes and tumour suppressors. [22] [23] [24] LncRNAs modulate gene expression at transcriptional and post-transcriptional levels via interacting with DNAs, proteins, mRNAs and/or microRNAs in different cellular contexts. [25] [26] [27] The expression, roles and clinical significances of several lncRNAs in glioma have also been reported. 28 Fu et al reported that lncRNA PVT1 is highly expressed in glioma and facilitates glioma tumorigenesis and progression. 29 Wang et al revealed that lncRNA-135528 inhibits glioma progression. 30 Liu et al found that lncRNA LINC00470 promoted glioma progression. 31 Xu et al identified that lncRNA AC003092.1 promotes glioma temozolomide chemosensitivity. 32 Although several lncRNAs have been investigated in glioma, the expression, roles and functional mechanisms of most other lncRNAs in glioma are still unknown.
In a previous report, Zhou et al compared the differentially expressed lncRNAs in 14 glioma tissues and five normal tissues using lncRNA microarray analysis. 33 Among these differentially expressed lncRNAs, we noted lncRNA LINC00526, which is markedly down- 
| MATERIAL S AND ME THODS

| Tissue samples
Human glioma tissues were obtained from 41 glioma patients who received surgery at the first affiliated hospital of Nanchang university (Nanchang, Jiangxi, China). Normal brain tissues were obtained from 11 patients who received brain tissue resection for craniocerebral injury at the first affiliated hospital of Nanchang university (Nanchang, Jiangxi, China). All tissues were pathologically diagnosed. Tissue samples were preserved at −80°C. The uses of tissue samples were reviewed and approved by the ethics committee of the first affiliated hospital of Nanchang university (Nanchang, Jiangxi, China). Written informed consents were obtained from all patients. 
| Cell culture and treatment
| RNA extraction, reverse transcription and quantitative real-time polymerase chain reaction (qRT-PCR)
Total RNA was extracted from indicated tissues or cells using the RNAiso Plus (Takara, Dalian, China), followed by treatment with (sense) and 5′-TTCACGGTTGGTATTTCGG-3′ (antisense); for AXL, 5′-CACCTCCCTGCAGCTTTC-3′ (sense) and 5′-CTCAG GTTGAAGGGGGTG-3′ (antisense) 34 ; and for GAPDH, 5′-GGTCTC CTCTGACTTCAACA-3′ (sense) and 5′-GTGAGGGTCTCTCTCTT CCT-3′ (antisense). 35 GAPDH was employed as an endogenous control. The quantification of the expression of RNAs was calculated by the 2 −ΔΔCt method.
| Plasmids construction
LINC00526 full-length sequences were PCR-amplified by the PfuUltra II Fusion HS DNA Polymerase (Agilent Technologies, Santa Clara, CA, USA) and the primers 5′-CGGGATCCGCGGACTCCGCGGACAAG-3′ (sense) and 5′-GGAATTCCAAAATGCATCTTGTTTATTTGGC-3′ (antisense).
Then, the PCR products were cloned into the BamH I and EcoR I sites of pcDNA TM 3.1(+) (Invitrogen) and pSPT19 (Roche, Mannheim, Germany)
plasmids, named as pcDNA-LINC00526 and pSPT19-LINC00526, respectively. The cDNA oligonucleotides silencing LINC00526 were synthesized by GenePharma (Shanghai, China) and inserted into the GenePharma SuperSilencing TM shRNA expression plasmid pGPU6/Neo.
The shRNAs target sites were 5′-GCTCAATGTCTCATAGCTACA-3′
(shLinc-1) and 5′-GGTCCTCCAAGATGAGCTTAA-3′ (shLinc-2). AXL ORF expression plasmid (Catalog EX-Z7835-M68) was purchased from GeneCopoeia (Guangzhou, China).
| Small interfering RNA (siRNA) synthesis and transfection
AXL specific and control Stealth siRNAs (siRNA ID HSS100897)
were purchased from Thermo Fisher Scientific (Waltham, MA, USA).
The transfection of plasmids and siRNAs was carried out by the Lipofectamine 3000 (Invitrogen) following the protocol.
| Stable cell lines construction
To obtain LINC00526 stably ectopically expressed glioma cells, and analysed by counting at least five random fields.
| Cell proliferation assays
| Cell migration and invasion assays
Transwell migration and invasion assays were undertaken to evaluate the cell migration and invasion potential. Indicated glioma cells resuspended in serum-free medium were seeded into the upper chamber of 24-well inserts with 8 μm pores (Millipore, Billerica, MA, USA). For invasion assay, the upper chamber was pre-coated with Matrigel (BD Biosciences, San Jose, CA, USA).
Medium containing 10% FBS was added to lower chamber.
After culture at 37°C for 48 hours, the cells remaining on the upper chamber were scraped off, and while those on the lower side of chamber were fixed, stained and observed using a Zeiss
Photomicroscope. The results were analysed by counting at least five random fields.
| Cytoplasmic and nuclear RNA purification
Cytoplasmic and nuclear RNA were purified from U87 cells using the Cytoplasmic & Nuclear RNA Purification Kit (Norgen, Belmont, CA, USA) following the instruction. After purification, the RNA was used for reverse transcription and qRT-PCR as above described. U6 was employed as nuclear control, and while β-actin was employed as cytoplasmic control. The primers used were as follows: for LINC00526, 5′-TTCAGGCTTCTGGGTCTC-3′ (sense) and 5′-TTCACGGTTGGTATTTCGG-3′ (antisense); for U6, 5′-GCTTCG GCAGCACATATACTAAAAT-3′ (sense) and 5′-CGCTTCACGA ATTTGCGTGTCAT-3′ (antisense) 35 and for β-actin, 5′-GGGAAAT CGTGCGTGACATTAAG-3′ (sense) and 5′-TGTGTTGGCGTACAGGT CTTTG-3′ (antisense). (antisense) and for GAPDH, 5′-GGTCTCCTCTGACTTCAACA-3′ (sense) and 5′-GTGAGGGTCTCTCTCTTCCT-3′ (antisense). 
| Western blot
Total cell lysates were isolated from indicated glioma cells by the 
| Chromatin immunoprecipitation (ChIP) assay
ChIP assay was undertaken using indicated glioma cells with the EZMagna ChIP™ A/G Chromatin Immunoprecipitation Kit (Millipore) and EZH2 specific primary antibody (Millipore), NFKB1 specific primary antibody (Sigma-Aldrich, Saint Louis, MO, USA) or NFKB2 specific primary antibody (Sigma-Aldrich) following the protocol. The enriched DNA was measured by qRT-PCR as above described. The primers used were as follows: for LINC00526 promoter, 5′-CCCGACTGTTTCCTACCC-3′
(sense) and 5′-GCCTCCCGACTTTTTGATG-3′ (antisense); for AXL promoter, 5′-GAGTGAGGGGGAATGAAGG-3′ (sense) and 5′-TCTGGGCTCTGTGTCTGGT-3′ (antisense). 
| Statistical analysis
| RE SULTS
| LINC00526 was lowly expressed in glioma
We first measured LINC00526 expression level in 41 glioma tissues and 11 normal tissues. As shown in Figure 1A , LINC00526 was F I G U R E 1 LINC00526 was lowly expressed in glioma. A, LINC00526 expression levels in 25 glioma tissues (III-VI), 16 glioma tissues (I-II) and 11 normal tissues were measured by qRT-PCR. Results are shown as median with interquartile range. *P < 0.05, **P < 0.01, ***P < 0.001, Kruskal-Wallis test followed by Dunn's multiple comparison test. B, Kaplan-Meier survival analyses of the correlation between LINC00526 expression level and overall survival of brain lower grade glioma patients (n = 510) from TCGA data. LINC00526 median expression level was used as cut-off. P = 0.0022, log-rank test. C, LINC00526 expression levels in normal glia cell line NHA and glioma cell lines LN18, U87, U251 and U138 were measured by qRT-PCR. Results are shown as mean ± SD of three independent experiments. ***P < 0.001, one-way ANOVA followed by Dunnett's multiple comparison test obviously lowly expressed in glioma tissues compared with normal tissues. Moreover, LINC00526 was further decreased in aggravated glioma tissues ( Figure 1A ). The Cancer Genome Atlas (TCGA) data revealed that lower expression of LINC00526 was associated with shorter survival time in brain low grade glioma patients ( Figure 1B ).
Furthermore, LINC00526 expression level in normal glia cell line NHA and glioma cell lines LN18, U87, U251 and U138 was measured.
The results showed that LINC00526 was lowly expressed in glioma cell lines compared with normal glia cell line ( Figure 1C ). Thus, these results indicated that LINC00526 was lowly expressed in glioma.
Low expression of LINC00526 was associated with the aggravation and poor prognosis of glioma.
| Ectopic expression of LINC00526 inhibited the proliferation, migration and invasion of glioma cells
To determine the influences of LINC00526 on glioma cells, we stably ectopically expressed LINC00526 in U87 and U251 cells ( Thus, these results indicated that ectopic expression of LINC00526 inhibited the proliferation, migration and invasion of glioma cells.
| LINC00526 silencing promoted the proliferation, migration and invasion of glioma cells
To further confirm the tumour suppressive roles of LINC00526 in glioma, we stably silenced the expression of LINC00526 in U87
and U251 cells using two independent LINC00526 specific shRNAs ( Figure 3A,3) . CCK-8 assays revealed that silencing of LINC00526 obviously increased the proliferation rate of U87 and U251 cells ( Figure 3C,3) . Moreover, EdU incorporation assays further supported the roles of LINC00526 silencing in promoting the proliferation of U87 and U251 cells ( Figure 3E ). Transwell migration assays revealed that LINC00526 silencing significantly promoted the migration of U87 and U251 cells ( Figure 3F ). Transwell invasion assays revealed that LINC00526 silencing significantly promoted the invasion of U87 and U251 cells ( Figure 3G ). Thus, these results indicated that LINC00526 silencing promoted the proliferation, migration and invasion of glioma cells.
| The expression of LINC00526 was inversely correlated with that of AXL in glioma tissues
To investigate the potential mechanisms mediating the tumour suppressive roles of LINC00526 in glioma, we analysed the expression correlations between LINC00526 and mRNAs in glioma tissues using TCGA data. Among the mRNAs whose expressions are correlated with LINC00526, we noted AXL, which is a receptor tyrosine kinase and has critical oncogenic roles in many cancers including glioma. 36, 37 As shown in Figure 4A , AXL mRNA expression was significantly inversely correlated with that of LINC00526 in glioma tissues (r = −0.4249, P = 0.0022). In contrast to LINC00526, higher expression of AXL was associated with shorter survival time in glioma patients ( Figure 4B ).
| LINC00526 repressed AXL transcription via interacting with EZH2
To determine the potential influences of LINC00526 on AXL, we first confirmed the subcellular location of LINC00526. The subcellular location of LINC00526 was predicted by lncLocator (http:// www.csbio.sjtu.edu.cn/bioin f/lncLo cator/ ). 38 The results predicted that LINC00526 was located in the nucleus with a score of 0.63.
Next, we performed cytoplasmic and nuclear RNA purification using U87 cells. The location of LINC00526 was measured by qRT-PCR.
The results showed that LINC00526 was mainly located in the nucleus ( Figure 5A ). Many nuclear lncRNAs were reported to interact with chromatin-modifying complexes and modulate genes expression. 17 About 20% nuclear lncRNAs were found to bind EZH2, a critical component of polycomb repressive complex 2 (PRC2). 39 Interestingly, EZH2 was also reported to activate AXL transcription. 34 Therefore, we further explore whether LINC00526 also binds EZH2 and whether LINC00526 influences AXL transcription via binding EZH2. RIP assays were performed in U87 cells. The results
showed that LINC00526 was specifically enriched in EZH2 antibody group, which indicated the binding between LINC00526 and EZH2
( Figure 5B ). Furthermore, RNA pulldown assays were performed using in vitro transcribed LINC00526 in U87 and U251 cells. As shown in Figure 5C , EZH2 was specifically enriched in LINC00526 group, which further supported the binding between LINC00526 and EZH2.
Then, we investigated whether the binding between LINC00526 and EZH2 influences the binding of EZH2 on AXL promoter. ChIP assays using EZH2 specific antibody were performed in LINC00526 stably overexpressed and control U87 cells. As shown in Figure 5D , ectopic expression of LINC00526 decreased the binding of EZH2 on AXL promoter. ChIP assays using EZH2 specific antibody were also performed in LINC00526 stably silenced and control U251 cells. The results showed that LINC00526 silencing increased the binding of EZH2 on AXL promoter ( Figure 5E ). EZH2 was reported to activate AXL transcription in glioma cells. Next, the mRNA and protein levels of AXL in LINC00526 stably overexpressed and control U87 cells, and LINC00526 stably silenced and control U251 cells were measured by qRT-PCR and Western blot. As shown in Figure 5F -I, ectopic expression of LINC00526 decreased the mRNA and protein levels of AXL, and while LINC00526 silencing increased the mRNA and protein levels of AXL. As a receptor tyrosine kinase, AXL is well-known to activate downstream PI3K/Akt/NF-κB signalling. Next, we investigated the influences of LINC00526 on PI3K/Akt/NF-κB signalling.
As shown in Figure 5J , ectopic expression of LINC00526 decreased the phosphorylation levels of Akt and IκBα. LINC00526 silencing increased the phosphorylation levels of Akt and IκBα ( Figure 5K ). Taken together, these results suggested that LINC00526 bound to EZH2, decreased the binding of EZH2 to AXL promoter, repressed AXL transcription and repressed PI3K/Akt/NF-κB signalling.
F I G U R E 2
Ectopic expression of LINC00526 repressed glioma cell proliferation, migration and invasion. A, LINC00526 expression levels in LINC00526 stably ectopically expressed and control U87 cells were measured by qRT-PCR. B, LINC00526 expression levels in LINC00526 stably ectopically expressed and control U251 cells were measured by qRT-PCR. C, Cell proliferation rates of LINC00526 stably ectopically expressed and control U87 cells were measured by CCK-8 assays. OD values in 450 nm were detected to indicate cell proliferation. D, Cell proliferation rates of LINC00526 stably ectopically expressed and control U251 cells were measured by CCK-8 assays. OD values in 450 nm were detected to indicate cell proliferation. E, Cell proliferation of LINC00526 stably ectopically expressed and control U87 and U251 cells were measured by EdU incorporation assays. Scale bars, 100 µm. F, Cell migration of LINC00526 stably ectopically expressed and control U87 and U251 cells were measured by transwell migration assays. Scale bars, 100 µm. G, Cell invasion of LINC00526 stably ectopically expressed and control U87 and U251 cells were measured by transwell invasion assays. Scale bars, 100 µm. Results are shown as mean ± SD of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, Student's t test promoter. These results supported the auto-regulatory roles of LINC00526 on itself.
| The tumour suppressive roles of LINC00526 in glioma were dependent on AXL
The above results showed that LINC00526 interacted with EZH2, repressed AXL transcription, and repressed PI3K/Akt/NF-κB signalling. AXL activated NF-κB signalling and repressed LINC00526 transcription. Therefore, LINC00526 and AXL formed a double negative feedback loop. Next, we investigated whether the tumour suppressive roles of LINC00526 in glioma are dependent on AXL.
We stably ectopically expressed AXL in LINC00526 stably overexpressed U87 cells ( Figure 7A ). CCK-8 assays revealed that ectopic expression of AXL abolished the decrease in proliferation rate caused by LINC00526 overexpression ( Figure 7B ). Moreover, EdU incorporation assays further supported the roles of ectopic expression of AXL in the reverse of the proliferation decrease caused by LINC00526 overexpression ( Figure 7C ). Transwell migration and invasion assays revealed that ectopic expression of AXL abolished the decrease in migration and invasion caused by LINC00526 overexpression ( Figure 7D,7) . In addition, we treated LINC00526 stably silenced and control U87 cells with AXL inhibitor R428. CCK-8 assays revealed that treatment with R428 blocked the increase in proliferation rate caused by LINC00526 silencing ( Figure 7F ).
Moreover, EdU incorporation assays further showed that treatment with R428 blocked the pro-proliferatory roles of LINC00526 silencing ( Figure 7G ). Transwell migration and invasion assays revealed that treatment with R428 blocked the increase in migration and invasion caused by LINC00526 silencing (Figure 7H,I ). Thus, these results indicated that the roles of LINC00526 in the proliferation, migration and invasion of glioma cells are dependent on the regulation of AXL.
F I G U R E 4
The expression levels of AXL were inversely correlated with that of LINC00526 in glioma tissues. A, The correlations between AXL expression level and LINC00526 expression level in brain lower grade glioma tissues (n = 510) from TCGA data. r = −0.4249, P = 0.0022, Pearson correlation analysis. B, Kaplan-Meier survival analyses of the correlation between AXL expression level and overall survival of brain lower grade glioma patients (n = 510) from TCGA data. AXL median expression level was used as cut-off. P < 0.0001, log-rank test F I G U R E 5 LINC00526 repressed AXL transcription via interacting with EZH2. A, LINC00526 subcellular location was detected by cytoplasmic and nuclear RNA purification, followed by qRT-PCR. U6 and β-actin were used as nuclear and cytoplasmic controls, respectively. B, RIP assays were performed in U87 cells using EZH2 specific antibody or nonspecific IgG. The enriched RNA was measured by qRT-PCR. HOTAIR was used as positive control, and while GAPDH was used as negative control. C, RNA pull-down assays were performed in U87 and U251 cells using in vitro transcribed biotin-labelled LINC00526 or antisense RNA. The enriched proteins were detected by Western blot with EZH2 specific antibody. D, ChIP assays were performed in LINC00526 stably ectopically expressed and control U87 cells using EZH2 specific antibody. The enriched DNA was measured by qRT-PCR and specific primers corresponding to AXL promoter. E, ChIP assays were performed in LINC00526 stably silenced and control U251 cells using EZH2 specific antibody. The enriched DNA was measured by qRT-PCR and specific primers corresponding to AXL promoter. F, AXL mRNA expression levels in LINC00526 stably ectopically expressed and control U87 cells were measured by qRT-PCR. G, AXL mRNA expression levels in LINC00526 stably silenced and control U251 cells were measured by qRT-PCR. H, AXL protein expression levels in LINC00526 stably ectopically expressed and control U87 cells were measured by Western blot. I, AXL protein expression levels in LINC00526 stably silenced and control U251 cells were measured by Western blot. J, Phosphorylation levels of Akt and IκBα in LINC00526 stably ectopically expressed and control U87 cells were measured by Western blot. K, Phosphorylation levels of Akt and IκBα in LINC00526 stably silenced and control U251 cells were measured by Western blot. **P < 0.01, ***P < 0.001, ns, not significant, Student's t test (B, D, F) or one-way ANOVA followed by Dunnett's multiple comparison test (E, G) F I G U R E 6 AXL repressed LINC00526 transcription via activating NF-κB signalling. A, Schematic outlining the predicted binding sites of NFKB1/NFKB2 on LINC00526 promoter. B, AXL protein levels in U251 cells after transient overexpressing AXL were measured by Western blot. C, ChIP assays were performed in U251 cells after transient overexpressing AXL using NFKB1, NFKB2 specific antibody or non-specific IgG. The enriched DNA was measured by qRT-PCR and specific primers corresponding to LINC00526 promoter. D, AXL protein levels in U87 cells after transient silencing AXL were measured by Western blot. E, ChIP assays were performed in U87 cells after transient silencing AXL using NFKB1, NFKB2 specific antibody or non-specific IgG. The enriched DNA was measured by qRT-PCR and specific primers corresponding to LINC00526 promoter. F, LINC00526 expression levels in U251 cells after transient overexpressing AXL were measured by qRT-PCR. G, LINC00526 expression levels in U87 cells after transient silencing AXL were measured by qRT-PCR. H, LINC00526 expression levels in U251 cells after transient overexpressing AXL and treated with 10 μM Andrographolide for 2 days were measured by qRT-PCR. I, ChIP assays were performed in LINC00526 stably overexpressed and control U87 cells using NFKB1, NFKB2 specific antibody or nonspecific IgG. The enriched DNA was measured by qRT-PCR and specific primers corresponding to LINC00526 promoter. J, ChIP assays were performed in LINC00526 stably silenced and control U251 cells using NFKB1, NFKB2 specific antibody or non-specific IgG. The enriched DNA was measured by qRT-PCR and specific primers corresponding to LINC00526 promoter. **P < 0.01, ***P < 0.001, ns, not significant, Student's t test (C, E, F, G, I) or one-way ANOVA followed by Dunnett's multiple comparison test (H, J)
The tumour suppressive roles of LINC00526 in glioma were dependent on AXL. A, AXL protein levels in LINC00526 and AXL concurrently stably ectopically expressed and control U87 cells were measured by Western blot. B, Cell proliferation rates of LINC00526 and AXL concurrently stably ectopically expressed and control U87 cells were measured by CCK-8 assays. OD values in 450 nm were detected to indicate cell proliferation. C, Cell proliferation of LINC00526 and AXL concurrently stably ectopically expressed and control U87 cells were measured by EdU incorporation assays. Scale bars, 100 µm. D, Cell migration of LINC00526 and AXL concurrently stably ectopically expressed and control U87 cells were measured by transwell migration assays. Scale bars, 100 µm. E, Cell invasion of LINC00526 and AXL concurrently stably ectopically expressed and control U87 cells were measured by transwell invasion assays. Scale bars, 100 µm. F, Cell proliferation rates of LINC00526 stably silenced and control U87 cells treated with 1 μM R428 were measured by CCK-8 assays. OD values in 450 nm were detected to indicate cell proliferation. G, Cell proliferation of LINC00526 stably silenced and control U87 cells treated with 1 μM R428 were measured by EdU incorporation assays. Scale bars, 100 µm. D, Cell migration of LINC00526 stably silenced and control U87 cells treated with 1 μM R428 were measured by transwell migration assays. Scale bars, 100 µm. E, Cell invasion of LINC00526 stably silenced and control U87 cells treated with 1 μM R428 were measured by transwell invasion assays. Scale bars, 100 µm. Results are shown as mean ± SD of three independent experiments. *P < 0.05, **P < 0.01, ns, not significant, one-way ANOVA followed by Dunnett's multiple comparison test (B-E) or Student's t test (F-I)
| D ISCUSS I ON
In this study, we identified a novel lncRNA LINC00526, which is down-regulated and functions as a tumour suppressor in glioma.
We first confirmed the significant down-regulation of LINC00526 in human glioma tissues. LINC00526 expression levels were inversely correlated with aggravation of glioma. Second, the correlation be- Although the expression and roles of several lncRNAs in glioma have been sufficiently investigated, the molecular mechanisms mediating the roles of lncRNAs and the reasons contributing to the dysregulation of lncRNAs in glioma are relative less investigated. In this study, we further explored the molecular mechanisms mediating the down-regulation and tumour suppressive roles of LINC00526 in glioma. Through searching TCGA data, we found that the expression of AXL was significantly inversely associated with that of LINC00526 in glioma tissues. AXL is a well-known receptor tyrosine kinase. 37 Several reports have revealed that AXL is overexpressed in human glioma and predicts poor prognosis of glioma patients. 50, 51 AXL was also reported to promote glioma growth, migration, invasion, tumorigenesis and primary resistance to EGFR inhibition. 37, 52, 53 The inverse expression patterns and inverse biological roles between LINC00526 and AXL implied that whether there is negative modulation between LINC00526 and AXL.
The molecular mechanisms mediating the roles of lncRNAs are complex and diverse. 25, 28 As a class of regulatory RNAs, lncRNAs directly bind proteins, DNAs, mRNAs and/or microRNAs. 35 Through interacting with other molecules, lncRNAs regulate the expression, location and/or functions of the interacting partners. 35 In this study, we identified that LINC00526 directly interacted with EZH2, which is a histone lysine methyltransferase and epigenetically modulates target genes expression. 54, 55 In a previous report, Ott et al showed that EZH2 induces AXL transcription. 34 In this study, we further Several feedback regulatory loops have been identified in cancers. 13, 56 The feedback regulatory loops could enlarge their modulatory roles in control gene expression and biological effects in cancers. 13, 56 Because AXL/PI3K/Akt/NF-κB signalling also regulates other genes, the effects of LINC00526 on these targets need further investigation.
In summary, this study identified a novel lncRNA LINC00526, which is lowly expressed in glioma. The down-regulation of LINC00526 was correlated with aggravation and poor prognosis.
LINC00526 inhibited glioma cell proliferation, migration and invasion via the LINC00526/EZH2/AXL/NF-κB/LINC00526 feedback loop. Thus, this study identified LINC00526 as a potential prognostic biomarker and a candidate for therapy in glioma.
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